11 results about "Joint swelling" patented technology

The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.

The application discloses application of a medicine composition in preparation of a medicine for treating rheumatoid arthritis (RA), and belongs to the field of RA treating medicines. The medicine composition is composed of swertiamarin (SW) and neochlorogenic acid (NCA) and is screened from two active ingredients in Danteng Yimu Decoction. With the help of animal model and cell model experiments, the action mechanism of the medicine composition in treating RA is explored, the related symptoms and indexes of collagen-induced arthritis (CIA) rats can be effectively improved, joint swelling can be relieved, arthritis inflammation index can be reduced, inflammatory factor release can be inhibited, joint bone quality can be protected, arthritis inflammation infiltration and cartilage destruction can be reduced, and the medicine safety is good. The composition can effectively inhibit the inflammatory factor release and migration ability of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Animal experiments and cell experiments prove that the combination of neochlorogenic acid and swertiamarin (SW+NCA) can be effectively applied to clinical treatment of RA and has a wide application prospect.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of psoralen in the preparation of drugs for the prevention and treatment of rheumatoid arthritis. This invention aims to address the problem of insufficient efficacy and inadequate clinical needs of existing rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of psoralen against rheumatoid arthritis. Studies have confirmed that psoralen can effectively inhibit the secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS cell proliferation, migration, and invasion, significantly improve joint swelling and weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint pathological damage. It blocks the pathological processes of rheumatoid arthritis, including inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural plant-derived component. This invention provides a novel natural drug option for the treatment of rheumatoid arthritis, effectively improving the existing treatment system for the disease.

This invention belongs to the field of traditional Chinese medicine preparation technology, and provides a traditional Chinese medicine composition with anti-inflammatory, swelling-reducing, analgesic, and joint-relieving properties, its preparation method, and its application in the preparation of drugs for treating arthralgia. The method includes the following steps: Smilax glabra, Corydalis yanhusuo (processed with vinegar), and Stephania tetrandra are pulverized, mixed, decocted with water, filtered, the filtrate is concentrated, ethanol is added to precipitate, the supernatant is collected, the ethanol is recovered and concentrated to obtain a water-extracted alcohol-immersed extract, which is then mixed with maltodextrin, wet-granulated, and dried to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition obtained by this invention is based on the principles of promoting joint mobility, reducing swelling and relieving pain. It can significantly inhibit ankle joint swelling in rats with gouty arthritis, improve local inflammatory cell infiltration, and reduce synovial tissue hyperplasia in rats with gouty arthritis.

This application belongs to the field of biomedical technology, specifically providing the application of human activated NK cells in the preparation of drugs for treating systemic juvenile idiopathic arthritis. Human activated NK cells derived from umbilical cord blood are intravenously infused at an optimal regimen of 3×10⁶-5×10⁶ cells / individual, once every 3 days for a total of 2 times. This significantly reduces the levels of IL-6, TNF-α, and SAA in the sJIA model, alleviates joint swelling, promotes weight recovery, reduces spleen index, and inhibits cytokine storm. The therapeutic effect can be maintained for at least 14 days without rebound. It has high safety, no obvious liver and kidney damage, and is suitable for clinical translational application.

The application discloses a composite soft capsule for relieving osteoarthritis, joint swelling and maintaining cartilage health and a preparation method thereof. First, oyster calcium is uniformly mixed with mono- and di-glycerol fatty acid esters and heated to obtain pretreated calcium powder; beeswax is dissolved in ethyl acetate to prepare a beeswax solution, the pretreated calcium powder is added to prepare a suspension, anhydrous ethanol is added dropwise, and the beeswax is precipitated through a reverse solvent with the calcium powder as a core, and then the modified oyster calcium is prepared through cooling and solidification, solvent removal by suction filtration and vacuum drying. The modified calcium powder and colostrum basic protein are dispersed in perilla seed oil, and phosphorus shrimp oil is compounded and homogenized to obtain a content, and then a capsule shell is matched to press a pill to obtain a finished product. The oyster calcium is subjected to surface hydrophobic modification, the problem of easy agglomeration and sedimentation of the oyster calcium in an oil phase is solved, a solid oil interface is blocked to promote an oxidation reaction, the storage stability of alpha-linolenic acid, DHA and EPA is improved, calcium ion slow release absorption is realized, active oil and protein are synergized to jointly take effect, and osteoarthritis inflammation is effectively relieved, swelling is subsided, and cartilage structure is protected.

The application belongs to the technical field of microorganisms, and particularly relates to a high uric acid relieving Paracasei postbiotic and application thereof. Lacticaseibacillus paracasei The Paracasei (Probio-37) has a preservation number of CGMCC No. 18638. The postbiotic prepared by the strain stimulates the intestinal uric acid excretion pathway through the "gut-kidney axis", reduces the SUA level, adjusts the immune homeostasis, inhibits excessive inflammatory response, enhances the intestinal barrier integrity, effectively relieves local inflammatory response caused by urate crystals, and thus improves clinical symptoms such as joint swelling and pain, and has obvious therapeutic effect on hyperuricemia.